X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-23 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres | P - Purchase | $7.39 | +2,000 | 6,282,140 | 0% | +$14,785 | ||||||
| M | 2025-05-21 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | P - Purchase | $7.32 | +5,468 | 4,628,272 | 0% | +$40,002 | |||||
2025-05-22 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | P - Purchase | $7.29 | +675 | 284,953 | 0% | +$4,921 | ||||||
| D | 2025-05-22 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale+OE | $50.00 | -4,000 | 33,492 | -11% | -$200,000 | |||||
2025-05-21 | AEON | Aeon Biopharma, Inc. | Fischer Jost | Dir | P - Purchase | $0.49 | +60,000 | 266,785 | +29% | +$29,250 | ||||||
| D | 2025-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $11.88 | -2,689 | 110,172 | -2% | -$31,933 | |||||
| D | 2025-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale+OE | $11.88 | -2,317 | 96,990 | -2% | -$27,516 | |||||
| D | 2025-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $11.88 | -9,999 | 306,618 | -3% | -$118,743 | |||||
2025-05-21 | PHAT | Phathom Pharmaceuticals, Inc. | Topper James N | Dir | P - Purchase | $3.86 | +3,780 | 5,922,827 | 0% | +$14,609 | ||||||
| M | 2025-05-21 | ARQT | Arcutis Biotherapeutics, Inc. | Heron Patrick J | Dir | P - Purchase | $13.66 | +5,040 | 8,850,339 | 0% | +$68,821 | |||||
| M | 2025-05-21 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.77 | +4,200 | 23,649 | +22% | +$7,446 | |||||
2025-05-20 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Medical Officer | S - Sale | $4.08 | -6,421 | 402,583 | -2% | -$26,207 | ||||||
2025-05-20 | ARDX | Ardelyx, Inc. | Renz Justin A | CFO | S - Sale | $4.08 | -7,218 | 416,089 | -2% | -$29,460 | ||||||
2025-05-20 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $4.08 | -46,817 | 1,573,301 | -3% | -$191,079 | ||||||
2025-05-20 | ARDX | Ardelyx, Inc. | Kelliher Mike | See Remarks | S - Sale | $4.08 | -14,522 | 282,158 | -5% | -$59,270 | ||||||
2025-05-20 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | See Remarks | S - Sale | $4.08 | -5,992 | 311,731 | -2% | -$24,456 | ||||||
2025-05-20 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $4.08 | -2,507 | 316,806 | -1% | -$10,232 | ||||||
| D | 2025-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.95 | -100,000 | 1,077,197 | -8% | -$1,095,000 | |||||
2025-05-20 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $50.04 | -6,677 | 59,721 | -10% | -$334,128 | ||||||
2025-05-21 | ATOS | Atossa Therapeutics, Inc. | Quay Steven C | Pres, CEO | P - Purchase | $0.88 | +11,239 | 36,152 | +45% | +$9,887 | ||||||
2025-05-19 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | P - Purchase | $7.23 | +135 | 284,278 | 0% | +$976 | ||||||
| A | 2025-05-13 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | P - Purchase | $7.01 | +90 | 284,143 | 0% | +$631 | |||||
| M | 2025-05-20 | INSM | Insmed Inc | Desjardins Clarissa | Dir | P - Purchase | $66.68 | +3,025 | 70,032 | +5% | +$201,694 | |||||
| D | 2025-05-20 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $67.66 | -27,887 | 598,654 | -4% | -$1,886,957 | |||||
| D | 2025-05-20 | SPRY | Ars Pharmaceuticals, Inc. | Fitzpatrick Alexander A | GC | S - Sale+OE | $14.10 | -102,969 | 89,613 | -53% | -$1,451,513 | |||||
| D | 2025-05-20 | SPRY | Ars Pharmaceuticals, Inc. | Saunders Brent L | Dir | S - Sale+OE | $14.25 | -120,000 | 0 | -100% | -$1,710,024 | |||||
| D | 2025-05-20 | SPRY | Ars Pharmaceuticals, Inc. | Scott Kathleen D. | CFO | S - Sale+OE | $14.10 | -50,000 | 15,674 | -76% | -$705,165 | |||||
2025-05-20 | CORT | Corcept Therapeutics Inc | Robb Gary Charles | Chief Business Officer | S - Sale | $75.85 | -2,279 | 26,777 | -8% | -$172,862 | ||||||
| D | 2025-05-20 | KNSA | Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | COB, CEO | S - Sale+OE | $27.02 | -2,349 | 206,469 | -1% | -$63,470 | |||||
| D | 2025-05-20 | VRNA | Verona Pharma Plc | Sinha Vikas | Dir | S - Sale+OE | $9.39 | -160,000 | 74,440 | -68% | -$1,502,928 | |||||
2025-05-20 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $6.45 | -357 | 64,027 | -1% | -$2,301 | ||||||
2025-05-20 | RCKT | Rocket Pharmaceuticals, Inc. | Schwartz Jonathan David | See Remarks | S - Sale | $6.45 | -801 | 235,255 | 0% | -$5,163 | ||||||
2025-05-20 | RCKT | Rocket Pharmaceuticals, Inc. | Patel Kinnari | See Remarks | S - Sale | $6.45 | -767 | 573,628 | 0% | -$4,944 | ||||||
2025-05-20 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $6.45 | -2,253 | 1,193,044 | 0% | -$14,523 | ||||||
2025-05-20 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $6.45 | -587 | 149,163 | 0% | -$3,784 | ||||||
2025-05-22 | SLS | Sellas Life Sciences Group, Inc. | Kalin Katherine Bach | Dir | P - Purchase | $1.80 | +20,000 | 41,000 | +95% | +$36,000 | ||||||
| AD | 2025-04-29 | VRNA | Verona Pharma Plc | Sinha Vikas | Dir | S - Sale+OE | $8.92 | -160,000 | 74,440 | -68% | -$1,427,328 | |||||
| M | 2025-05-20 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $11.04 | -4,000 | 2,810,824 | 0% | -$44,160 | |||||
2025-05-21 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Pres, CEO | P - Purchase | $4.40 | +10,000 | 2,325,731 | 0% | +$43,995 | ||||||
2025-05-19 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $0.67 | -10,712 | 305,892 | -3% | -$7,177 | ||||||
2025-05-19 | NKTR | Nektar Therapeutics | Wilson Mark Andrew | GC | S - Sale | $0.67 | -9,996 | 314,296 | -3% | -$6,697 | ||||||
2025-05-19 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $0.67 | -23,208 | 1,064,103 | -2% | -$15,549 | ||||||
| D | 2025-05-20 | XOMA | Xoma Royalty Corp | Hughes Owen | CEO | S - Sale+OE | $25.38 | -25,637 | 64,996 | -28% | -$650,667 | |||||
| D | 2025-05-20 | XOMA | Xoma Royalty Corp | Burns Thomas M. | SVP, Finance, CFO | S - Sale+OE | $25.38 | -10,482 | 32,693 | -24% | -$266,033 | |||||
2025-05-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $16.31 | -5,000 | 985,188 | -1% | -$81,534 | ||||||
2025-05-19 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $16.49 | -5,000 | 972,892 | -1% | -$82,453 | ||||||
| M | 2025-05-19 | AEON | Aeon Biopharma, Inc. | Fischer Jost | Dir | P - Purchase | $0.50 | +110,000 | 206,785 | +114% | +$55,300 | |||||
| D | 2025-05-19 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $26.41 | -12,000 | 72,363 | -14% | -$316,920 | |||||
2025-05-19 | BPMC | Blueprint Medicines Corp | Rossi Christina | COO | S - Sale | $100.51 | -2,274 | 64,718 | -3% | -$228,557 | ||||||
2025-05-20 | PHIO | Phio Pharmaceuticals Corp. | Ferrara Robert L | Dir | P - Purchase | $1.82 | +2,500 | 13,166 | +23% | +$4,550 | ||||||
2025-05-21 | ZOMDF | Zomedica Corp. | Blair Anthony K | COO | P - Purchase | $0.05 | +100,000 | 1,000,000 | +11% | +$4,964 | ||||||
2025-05-20 | MDCX | Medicus Pharma Ltd. | Velocity Fund Partners, LP | 10% | S - Sale | $7.72 | -75,000 | 3,248,741 | -2% | -$578,940 | ||||||
2025-05-20 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $107.49 | -3,000 | 457,993 | -1% | -$322,473 | ||||||
2025-05-20 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $4.40 | -12,078 | 989,343 | -1% | -$53,143 | ||||||
2025-05-20 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $4.41 | -2,345 | 879,546 | 0% | -$10,341 | ||||||
2025-05-20 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $8.13 | -11,143 | 114,055 | -9% | -$90,593 | ||||||
2025-05-20 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $8.13 | -58,677 | 461,982 | -11% | -$477,044 | ||||||
| D | 2025-05-16 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $74.17 | -32,262 | 5,487 | -85% | -$2,393,014 | |||||
| D | 2025-05-19 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale+OE | $11.84 | -2,600 | 95,557 | -3% | -$30,791 | |||||
| D | 2025-05-19 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $11.84 | -3,808 | 293,367 | -1% | -$45,097 | |||||
| D | 2025-05-19 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $11.84 | -2,776 | 106,611 | -3% | -$32,876 | |||||
| D | 2025-05-16 | CORT | Corcept Therapeutics Inc | Mahoney David L | Dir | S - Sale+OE | $74.23 | -27,352 | 1,258,761 | -2% | -$2,030,452 | |||||
| DM | 2025-05-19 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale+OE | $33.38 | -101,156 | 6,011,537 | -2% | -$3,376,741 | |||||
2025-05-16 | RLMD | Relmada Therapeutics, Inc. | Kelly Paul Edward | COO | P - Purchase | $0.43 | +200,000 | 412,295 | +94% | +$86,060 | ||||||
| M | 2025-05-16 | RLMD | Relmada Therapeutics, Inc. | Shenouda Maged | CFO | P - Purchase | $0.49 | +200,000 | 288,335 | +226% | +$97,208 | |||||
2025-05-16 | RLMD | Relmada Therapeutics, Inc. | Ence Chuck | CA, CO | P - Purchase | $0.45 | +228,961 | 267,931 | +588% | +$103,330 | ||||||
| M | 2025-05-16 | RLMD | Relmada Therapeutics, Inc. | Traversa Sergio | CEO | P - Purchase | $0.50 | +350,000 | 734,024 | +91% | +$174,713 | |||||
2025-05-20 | BMRN | Biomarin Pharmaceutical Inc | Burkhart Erin | GVP, Chief Accounting Officer | S - Sale | $59.31 | -1,786 | 14,173 | -11% | -$105,928 | ||||||
| D | 2025-05-20 | CNTA | Centessa Pharmaceuticals Plc | Saha Saurabh | CEO | S - Sale+OE | $12.71 | -55,000 | 259,017 | -18% | -$699,111 | |||||
2025-05-19 | ARQT | Arcutis Biotherapeutics, Inc. | Edwards Larry Todd | See Remarks | S - Sale | $14.07 | -7,451 | 183,104 | -4% | -$104,850 | ||||||
2025-05-16 | HCWB | Hcw Biologics Inc. | Wong Hing C | CEO, 10% | P - Purchase | $7.45 | +8,054 | 501,911 | +2% | +$60,002 | ||||||
2025-05-16 | HCWB | Hcw Biologics Inc. | Winer Gary M | Dir | P - Purchase | $7.45 | +1,342 | 4,075 | +49% | +$9,998 | ||||||
2025-05-16 | HCWB | Hcw Biologics Inc. | Garrett Scott T | Dir | P - Purchase | $7.45 | +13,423 | 25,505 | +111% | +$100,001 | ||||||
| D | 2025-05-15 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $295.11 | -11,000 | 36,781 | -23% | -$3,246,150 | |||||
| D | 2025-05-20 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $31.98 | -2,000 | 140,255 | -1% | -$63,960 | |||||
2025-05-08 | MTVA | Metavia Inc. | Dong-A St Co., Ltd | 10% | P - Purchase | $0.71 | +4,647,887 | 9,995,679 | +87% | +$3,300,000 | ||||||
2025-05-16 | IRWD | Ironwood Pharmaceuticals Inc | McCourt Thomas A | CEO | S - Sale | $0.58 | -13,353 | 1,687,281 | -1% | -$7,745 | ||||||
2025-05-16 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $0.58 | -2,563 | 242,596 | -1% | -$1,487 | ||||||
2025-05-16 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $6.53 | -655 | 64,384 | -1% | -$4,276 | ||||||
2025-05-16 | RCKT | Rocket Pharmaceuticals, Inc. | Patel Kinnari | See Remarks | S - Sale | $6.53 | -1,409 | 574,395 | 0% | -$9,198 | ||||||
2025-05-16 | RCKT | Rocket Pharmaceuticals, Inc. | Schwartz Jonathan David | See Remarks | S - Sale | $6.53 | -1,582 | 236,056 | -1% | -$10,327 | ||||||
2025-05-16 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $6.53 | -3,621 | 1,195,297 | 0% | -$23,638 | ||||||
2025-05-16 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $6.53 | -946 | 149,750 | -1% | -$6,175 | ||||||
| M | 2025-05-16 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $11.21 | -4,000 | 2,814,824 | 0% | -$44,840 | |||||
2025-05-19 | ZOMDF | Zomedica Corp. | Dehaan-Fullerton Karen | GC, Corporate Secy | P - Purchase | $0.05 | +104,300 | 104,300 | New | +$5,006 | ||||||
2025-05-19 | ZOMDF | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.05 | +500,000 | 3,425,000 | +17% | +$23,000 | ||||||
| M | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Delshad Jim | Dir | P - Purchase | $7.31 | +5,100 | 55,310 | +10% | +$37,258 | |||||
2025-05-13 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | P - Purchase | $7.01 | +90 | 367,231 | 0% | +$631 | ||||||
2025-05-12 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | P - Purchase | $7.00 | +400 | 4,582,349 | 0% | +$2,800 | ||||||
2025-05-16 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale | $22.50 | -4,000 | 20,395 | -16% | -$90,000 | ||||||
2025-05-16 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale | $25.00 | -2,000 | 62,130 | -3% | -$50,000 | ||||||
| D | 2025-05-15 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $39.30 | -10,000 | 95,034 | -10% | -$392,978 | |||||
| M | 2025-05-11 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres | P - Purchase | $10.65 | +10,000 | 8,037,594 | 0% | +$106,515 | |||||
| M | 2025-05-15 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.47 | +55,421 | 17,883,908 | 0% | +$635,586 | |||||
2025-05-19 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $5.96 | -1,559 | 107,948 | -1% | -$9,292 | ||||||
2025-05-19 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $6.28 | -1,558 | 21,367 | -7% | -$9,777 | ||||||
| D | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Chief Commercial Officer | S - Sale+OE | $6.26 | -3,927 | 35,161 | -10% | -$24,575 | |||||
| M | 2025-05-15 | CNTA | Centessa Pharmaceuticals Plc | Goyal Arjun | Dir | P - Purchase | $12.68 | +462,585 | 462,585 | New | +$5,865,242 | |||||
| D | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC | S - Sale+OE | $6.26 | -4,552 | 47,136 | -9% | -$28,486 | |||||
| D | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO, SECRETARY | S - Sale+OE | $6.26 | -4,282 | 265,231 | -2% | -$26,796 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |